Veraxa Biotech is trading 5.1% down today at $2.03 as part of a broader pullback in high-beta biotech stocks following last week’s sector rally and subsequent profit-taking.
- The stock is easing after its July 13 jump triggered by an AI-enabled drug discovery collaboration with Ardigen.
- There is no fresh company-specific news on July 14, 2026; the decline aligns with the broader biotech sector (XBI) trading lower.